Proceeds Will Further Advance Liprotamase Commercialization Efforts
CAMBRIDGE, Mass., January 28, 2010– Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors [...]
NEA Joins Syndicate; NEA’s David Mott Joins Board
CAMBRIDGE, Mass., December 8, 2009– Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M. Epizyme initially announced a $32M round led [...]
CAMBRIDGE, Mass., October 7, 2009– Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC). Joining BCC as new investors are Amgen Ventures and Astellas Venture Management. Existing investors [...]
Company poised to introduce its unique Quantitative Multiplexed Assay platform
MANSFIELD, Mass., September 21, 2009– PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company’s existing investors; [...]
Dr. Corey Goodman appointed chairman of iPierian – – MPM Capital leads new investment round of $11.5 million – – World-renowned scientists anchor new Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif. and BOSTON, July 8, 2009– iZumi Bio, Inc. and Pierian, Inc. today announced they have merged to form a new company, iPierian, Inc. Building on [...]
